This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Recursion Pharmaceuticals | |
|---|---|
| Name | Recursion Pharmaceuticals |
| Type | Public |
| Industry | Biotechnology |
| Founded | 2013 |
| Founder | Chris Gibson, Chris Bouton, Blake Andersen |
| Headquarters | Salt Lake City, Utah, United States |
| Key people | Brendan Frey, Chris Gibson, Chris Bouton |
| Products | Drug discovery platform, preclinical therapeutic candidates |
Recursion Pharmaceuticals is a biotechnology company that applies high-throughput biology, automated microscopy, and artificial intelligence to accelerate drug discovery. The company integrates technologies from computational biology, machine learning, and laboratory automation to identify therapeutic candidates across rare diseases and common indications. Recursion has engaged with academic institutions, pharmaceutical companies, and government agencies to scale phenotypic screening and computational chemistry efforts.
Recursion was founded in 2013 by entrepreneurs and scientists who previously worked on projects at institutions such as University of Utah, Stanford University, University of Oxford, University of California, San Francisco, and MIT. Early seed funding and accelerator relationships connected the company to ecosystems including Y Combinator, Techstars, Plug and Play Tech Center, and regional incubators in Salt Lake City. Growth phases featured board and executive interactions with figures from Pfizer, Genentech, Amgen, Novartis, and Eli Lilly and Company. Recursion’s public debut followed a series of private financings involving investors from firms like Sequoia Capital, Khosla Ventures, GV (formerly Google Ventures), and Lux Capital, leading to an initial public offering influenced by market activity at Nasdaq and comparative listings of biotech firms such as Moderna and Regeneron Pharmaceuticals.
Recursion operates at the intersection of experimental biology and computational sciences, leveraging automated laboratory platforms similar to systems used by Thermo Fisher Scientific and Beckman Coulter for high-throughput screening. Core technologies combine high-content imaging akin to platforms from GE Healthcare and PerkinElmer with machine learning frameworks drawn from research at Google DeepMind, OpenAI, and academic groups at Carnegie Mellon University and University of Toronto. The firm’s proprietary databases and image libraries echo resources like The Cancer Genome Atlas and Allen Institute for Brain Science in scale, enabling phenotype-driven candidate selection comparable to approaches by BenevolentAI and Insilico Medicine. Commercially, Recursion offers discovery collaborations, data licensing, and internal pipeline development reminiscent of business models from Vertex Pharmaceuticals and Bristol-Myers Squibb.
Recursion’s pipeline spans preclinical programs and early clinical candidates across disease areas including rare genetic disorders and immuno-oncology. Programs reference targets and pathways studied in literature from groups at Harvard Medical School, Johns Hopkins University, Massachusetts General Hospital, and Dana-Farber Cancer Institute. Screening sets include compounds similar to libraries maintained by NIH Clinical Collection, ChemBridge, and academic medicinal chemistry efforts at Scripps Research. Candidate progression strategies parallel those used by companies such as AstraZeneca and GlaxoSmithKline in translating phenotypic hits to lead optimization and IND-enabling studies overseen by regulators like Food and Drug Administration and European Medicines Agency. Collaborations with disease-specific foundations, analogous to work by Cystic Fibrosis Foundation and Michael J. Fox Foundation, inform prioritization of orphan indications.
Recursion has formed strategic alliances with pharmaceutical companies, academic centers, and non-profit organizations. Notable collaborations have involved joint programs and data-sharing agreements resembling partnerships between Roche and Regeneron Pharmaceuticals, or consortia like the Structural Genomics Consortium. Academic partnerships with institutions such as University of California, San Diego, Columbia University, Yale School of Medicine, and University College London have supported validation studies. Corporate collaborations with firms analogous to Bayer and Takeda include co-development and licensing constructs used by Gilead Sciences in prior deals. Government and philanthropic links echo engagements by biotechnology firms with agencies including National Institutes of Health and initiatives comparable to those led by Bill & Melinda Gates Foundation.
Recursion’s capital strategy has included seed rounds, venture financings, and public equity offerings involving investors like Sequoia Capital, Khosla Ventures, DCVC (Data Collective), and Casdin Capital. Financial milestones referenced public market activity at Nasdaq and valuation comparisons to peers such as Illumina and Sarepta Therapeutics. Revenue streams derive from collaborative research agreements, milestone payments, and potential royalty structures similar to contracts negotiated by companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Financial scrutiny from analysts at firms including Goldman Sachs, Morgan Stanley, and JP Morgan has paralleled reporting practices in the biotechnology sector.
Clinical development strategies align with regulatory frameworks employed by the Food and Drug Administration, European Medicines Agency, and agencies in markets such as Japan and Canada. Progression from IND submission through Phase 1/2 trials mirrors pathways taken by biotechnology companies including Bluebird Bio and Sarepta Therapeutics, with attention to orphan drug designations and expedited programs like Breakthrough Therapy designation. Trial design and endpoint selection have drawn on methodologies from academic trials at Mayo Clinic and Cleveland Clinic. Safety monitoring and pharmacovigilance reference standards used by regulators and organizations such as World Health Organization.
Critiques of Recursion’s approach reflect broader debates about data-driven drug discovery, including reproducibility concerns raised in literature from Nature, Science, and Cell Press publications. Discussions among venture stakeholders and policy commentators at outlets like The Wall Street Journal, The New York Times, and Financial Times have examined capital allocation and valuation in platform biotech. Bioethical commentaries referencing panels at National Academies of Sciences, Engineering, and Medicine and debates at conferences such as BIO International Convention have debated transparency, data sharing, and prioritization of rare-disease versus high-prevalence indications. Academic critics from institutions like Princeton University and University of Chicago have published on challenges in translating high-content phenotypic hits into clinically effective therapies.
Category:Biotechnology companies